Logotype for Novolog (Pharm-Up 1966) Ltd

Novolog (NVLG) Q3 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Novolog (Pharm-Up 1966) Ltd

Q3 2025 earnings summary

6 Nov, 2026

Executive summary

  • Q3 2025 revenue was ₪483.6m and net income was ₪4.3m, down year over year; 9M revenue was ₪1,432.1m and net income rose to ₪41.0m from ₪38.3m.

  • Logistics, healthcare and digital health were profitable; logistics was pressured by SAP rollout disruption, one-off expenses and higher ongoing costs.

Financial highlights

  • Q3 revenue was ₪483.6m versus ₪550.9m YoY; gross profit was ₪37.1m versus ₪44.4m, and operating profit was ₪10.2m versus ₪16.9m.

  • 9M revenue was ₪1,432.1m versus ₪1,482.7m; gross profit fell 23.5% to ₪104.3m, while net income increased to ₪41.0m from ₪38.3m.

  • 9M operating cash flow was ₪158.5m versus ₪118.1m; investing cash outflow was ₪50.5m, including ₪48.5m invested in fixed and intangible assets.

  • Cash and cash equivalents were ₪247.6m at September 30, 2025, versus ₪239.9m a year earlier; total assets were ₪3,037.1m.

Outlook and guidance

  • 2025 Adjusted EBITDA guidance was ₪96–102m, excluding extraordinary events.

  • Estimated 2025 financial impact from SAP implementation was ₪18m–₪22m; ₪14.9m was recognized as one-off expenses in 9M, with most remaining impact tied to lower ongoing revenue.

  • Most SAP stabilization work was complete; mitigation included customer negotiations, retention measures and a logistics efficiency plan.

  • Plans included expanding health-services projects and offerings, and upgrading the digital appointment-booking system.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Novolog